Navigation Links
Afinitor (Breast Cancer) - Analysis and Forecasts to 2020
Date:10/20/2011

r, Selected Countries, 1975-2005 12

Figure 9: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12

Figure 10: Breast Cancer, Mortality, Worldwide, 2008-2030 13

Figure 11: All Cancers, Mortality, Worldwide, 2008-2030 13

Figure 12: Broad Classification of Breast Cancer, By Type 15

Figure 13: Classification of Non-Invasive Breast Cancer, By CIS 15

Figure 14: Classification of Invasive Breast Cancer, By Stages 16

Figure 15: Classification of Invasive Breast Cancer, By Treatment 16

Figure 16: Classification of Metastatic or Advanced Breast Cancer 16

Figure 17: Classification of Early Stage Breast Cancer (Excluding Stage 0) 17

Figure 18: Classification of Locally Advanced Breast Cancer 17

Figure 19: Metastatic Breast Cancer Classification 17

Figure 20: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 18

Figure 21: Breast Cancer Intrinsic Sub Types used for Deciding Treatment Options for MBC 19

Figure 22: Breast Cancer Types in Decreasing Order of their Aggressiveness 19

Figure 23: Treatment Options, DCIS Breast Cancer 20

Figure 24: Treatment Options, LCIS Breast Cancer 21

Figure 25: Treatment Options, Stages I, II and IIIA 21

Figure 26: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 22

Figure 27: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 22

Figure 28: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 23

Figure 29: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 24

Figure 30: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 24

Figure 31: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 26

Figure 32: Treatment Options, HR Negative and HER2 Positive Metasta
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
2. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
3. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
4. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
5. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
6. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
7. Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
8. FDA Approves New Indication for Afinitor
9. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
10. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
11. Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... N.Y. , May 21, 2013  Vasomedical, Inc. (OTC ... in the design, manufacture and sale of medical devices and ... that Dr. Jun Ma , President and ... Marcum LLP MicroCap Conference on Thursday, May 30, 2013 in ... Hyatt Hotel. The Company,s presentation is scheduled ...
(Date:5/21/2013)... and TARRYTOWN, N.Y. , ... NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today ... published online the positive Phase 2a study results ...  Dupilumab is an investigational monoclonal antibody targeting the alpha ... modulates signaling of both IL-4 and IL-13, drivers of ...
(Date:5/21/2013)... , May 21, 2013  BioRestorative Therapies, Inc. ("BRT" ... company focused on developing stem cell based therapies for ... , its President and CEO, will be presenting ... conference will be held on Thursday, May 30, 2013 ... 42nd Street in New York City.  Mr. Weinreb,s presentation ...
Breaking Medicine Technology:Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3
... Inc., a privately-held developer and marketer of the ... system for measuring platelet reactivity to multiple antiplatelet ... published in The Annals of Thoracic Surgery ... as a new recommendation for preoperative patient assessment(1). ...
... Pa., March 9, 2011 ViroPharma Incorporated (Nasdaq: ... has authorized the use of up to $150 million to ... Convertible Notes due 2017. Purchases may be ... negotiated purchase transactions or other techniques from time to time, ...
Cached Medicine Technology:2011 Surgical Guidelines Recommend Point-of-Care Platelet Reactivity Testing Prior to Surgery 22011 Surgical Guidelines Recommend Point-of-Care Platelet Reactivity Testing Prior to Surgery 3ViroPharma Announces Securities Repurchase Program 2ViroPharma Announces Securities Repurchase Program 3
(Date:5/21/2013)... genetic features of pulmonary fibrosis by physicians and scientists ... lead to improved treatment of this deadly lung disease, ... . , The study found that a particular genetic ... fibrosis, a chronic progressive disease with a median survival ... researchers may want to consider including genetic testing in ...
(Date:5/21/2013)... the adenoids and tonsils, is performed 500,000 times a ... for children with obstructive sleep apnea. However, the ... functioning, behavior, sleep apnea symptoms, and quality of life ... study led by Susan Redline, MD, MPH, director ... Associate Clinic Director of the Division of Sleep Medicine ...
(Date:5/21/2013)... Today, Zane Benefits, Inc. published a new ... Zane Benefits, which provides comprehensive and flexible alternatives to ... defined contribution and http://HRA Link: ... Zane Benefits’ website, the Affordable Care Act (known as ... 2010 and impacts many areas of health care and ...
(Date:5/21/2013)... 2013 A new study appearing in ... that stem cells harvested from fat (adipose) are more ... to modulate the body’s immune system. , The ... therapies, as adipose tissue-derived stem cells (AT-SCs) are far ... bone marrow and can be collected from waste material ...
(Date:5/21/2013)... 21, 2013 Octo Consulting Group, ... management consulting solutions to the Federal marketplace, has ... In the newly created role, Denny will ... of the firm’s business development function to include ... functions, and leading strategies to achieve the firm’s ...
Breaking Medicine News(10 mins):Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Early removal of adenoids and tonsils can help pediatric sleep apnea symptoms 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 3Health News:Octo Consulting Group Appoints Tracy Denny as Vice President of Business Development 2
... Department of Antiquities of Syria and the University of Chicago ... fought in upper Mesopotamia// in 3500 B.C., leading to the ... that the entire area where the excavation was conducted was ... by the archeologists. Hamoukar is in Syria at the Iraqi ...
... related to Food science and consumer acceptance in Norway ... then do experts to cheese.// ,The food compared ... with expert dairy assessors. The rating was based on ... ,There was difference of opinion in both factions. As ...
... will be spending $60 million to buy 1.8 courses ... //Australian Health Minister Tony Abbott confirmed the order yesterday. ... to pharmaceuticals giant GlaxoSmithKline, but Biota had alleged that ... this allegation. This fresh order makes it the third ...
... has been conducted on a six-year-old Pakistani boy at the ... his birthday on 19 December 2005. //,Anupam Sibal, Medical Director ... in ICU but is responding well to medication. Doctors are ... be normal soon.' , ,He refused to give further ...
... Yoga, Acupuncture, Ayurveda, Chinese movement therapies such as ... just some of the commonly used alternative treatments ... Europe. //Perhaps, this is because it’s strongly perceived ... treatment for cancer with the combination of some ...
... of James Cook University's (JCU) has urged the Health ... the University which will help to produce more doctors ... graduation day.// James Cook University is Australia's premier tropical ... The University is named after the British explorer, Captain ...
Cached Medicine News:Health News:Excavations Reveal Clues Of Early Warfare 2
... system was expressly designed to obtain the ... special source and an equally special power ... particular high energy impulses with constant peak ... 'top-flat shaped') allow storage of enough energy ...
... Derm is a KTP laser, very compact ... nm (frequency doubled Nd:YAG) for dermatologic treatments. ... comfortable color LCD Touch-screen. Maximum power ... 0.3, 0.5, 0.7 and 1.0 mm. SmartLite ...
... Erbium (Er:YAG) laser is the ideal instrument ... Smart 2940 Plus, the majority of surface ... a wide range of scar tissue, with ... most cases with the elimination of anaesthetics, ...
... is the result of DEKA s ... of three different methods capable of ... skin. This treatment is designed to ... through the combined action of a ...
Medicine Products: